2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…2018 American Transplant Congress
Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis
Objectives: Cytomegalovirus (CMV) is an opportunistic infection that can lead to significant complications post-transplant. Purpose of this study was to evaluate the use of valganciclovir…2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients.
BACKGROUND: Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can…2017 American Transplant Congress
Impact of Ritonavir on Graft Function in Human Immunodeficiency Virus Infected Kidney Transplant Recipients.
Emory University Hospital, Atlanta, GA
Purpose: The purpose of this study was to determine the difference in 6 and 12 month graft function between patients with human immunodeficiency virus (HIV)…2017 American Transplant Congress
Tenofovir Use Is Not Associated with Reduced Bone Density or Fractures in Liver Transplant Recipients.
University of Minnesota, Minneapolis, MN
BackgroundTenofovir disproxil fumarate (TDF) and reduced bone density in the HIV population is well-documented. The effect of TDF use on bone density in patients who…2017 American Transplant Congress
Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection.
Background:Influenza infection significantly impacts transplant patients. Despite this, there are limited data on how virological characteristics, including influenza viral load (VL), impact the outcome of…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »